BCL2 and cancer: Then, some researchers found lack of bcl-2 39, 40, PTEN 41, TIMP-2 42, ER and PR 43, decrease of hemoglobin 44, EpCAM 45, up-regulation of serum CA125 46, serum TIMP-1 47, ulex europeus agglutinin-I (UEA-I) 48, HIF-1α 49, aurora B 50, MMP-7 51, homeobox (HOX) transcript antisense intergenic RNA (HOTAIR) 52, CHRM3 53, AAA+ (ATPases associated with various cellular activities) nuclear coregulator cancer-associated (ANCCA) 54, glycogen synthase kinase-3β (GSK-3β) 55 can serve as a poor prognostic marker for EC patients.